Table 3

Patient characteristics by duration of diabetes
Diabetes duration (yrs) n (%)a Mean±SD HbA1c (%) Concomitant disease/ complication (%)b Achieved HbA1c <7.0% (%)b OAD (%)b Insulin + OAD (%)b GLP-1 RA + OAD (%)b
<1 36,337 (15.22) 8.12±1.99 12,663 (34.85) 11,007 (30.29) 26,372 (72.58) 9909 (27.27) 56 (0.15)
≥1-5 102,550 (42.97) 7.66±1.61 45,533 (44.40) 36,331 (35.43) 75,459 (73.58) 26,896 (26.23) 195 (0.19)
≥5-10 55,744 (23.36) 7.84±1.66 34,374 (61.67) 16,915 (30.34) 34,446 (61.79) 21,159 (37.96) 139 (0.25)
≥10 44,003 (18.44) 8.09±1.76 31,607 (71.83) 11,575 (26.31) 20,933 (47.57) 23,006 (52.28) 64 (0.15)
P valuec <0.0001 <0.0001 <0.0001 <0.0001 NS NS

aPercentage of patients among the full population; bPercentage of patients among the patients with particular diabetes duration; cANOVA and chi-square test were used as appropriate.

GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; NS = not significant; OAD, oral antidiabetes drug; SD, standard deviation.

Ji et al.

Ji et al. BMC Public Health 2013 13:602   doi:10.1186/1471-2458-13-602

Open Data